GlassScriptPhysician profile
Alyssa R Waitkus
NPI 1134214042
$1,159.19
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $841 · 2022: $224 · 2023: $93.85.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $93.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $93.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $328.07 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $268.44 | 2021-2022 | |
| Novo Nordisk INC | $145.92 | 2021-2023 | |
| Pfizer INC. | $59.02 | 2021-2022 | |
| Lilly USA, LLC | $52.53 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $38.23 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $29.76 | 2021 | |
| Amneal Pharmaceuticals LLC | $28.77 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.80 | 2021 | |
| Nestle Healthcare Nutrition INC. | $27.73 | 2021 | |
| Amgen INC. | $26.69 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $26.03 | 2021-2022 | |
| Esperion Therapeutics, INC. | $23.11 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $19.77 | 2022 | |
| Genentech USA, INC. | $18.42 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ultragenyx Pharmaceutical INC. | $15.65 | 2021 | |
| Eisai INC. | $11.97 | 2021 | |
| Glaxosmithkline, LLC. | $11.28 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alyssa Waitkus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.